There are more than 2000 scientific publications on Dulcolax and its ingredients. A short overview of the most important findings is given below. Simply click on the symbol below each text for further details about the reports listed here.
The Food and Drug Administration of the USA (FDA):
Bisacodyl, the active ingredient of Dulcolax, is “safe and effective”.
Boehringer Ingelheim USA completed extensive tests with Bisacodyl in 1999 under the supervision of the American health authorities (FDA) in an effort to investigate the carcinogenic and mutagenic potential of drugs. The FDA published its assessment in 2000: “From all the data available there are no signs to suggest a risk of cancer in humans if Bisacodyl is taken as recommended.” This data thus supports the allocation of Dulcolax to group I OTC products in the USA as safe and effective.
Bisacodyl absorption study:
This study was designed to investigate the absorption of Bisacodyl and the blood level patterns. It also attempted to correlate this with the evacuation effect. The study concluded: There is no correlation between the laxative effect of Bisacodyl and the blood level. According to the present findings, the laxative effect of the comfort-coated tablet and suppository is triggered by an interaction or direct contact of the substance in the lower part of the intestine.
American Gastroenterological Association (AGA) on 21 May 2000:
New guidelines on the management of constipation
Dulcolax is the product of choice:
- for constipation with delayed intestinal transport: Dulcolax or fibre or mineral salts.
- for constipation without delayed intestinal transport: Dulcolax where fibre or mineral salts are ineffective
- for disturbed rectal evacuation: behaviour therapy and biofeedback combined with administration of Dulcolax or fibre or mineral salts.